Journal
TRENDS IN NEUROSCIENCES
Volume 24, Issue 4, Pages 219-224Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/S0166-2236(00)01749-5
Keywords
-
Categories
Funding
- NIA NIH HHS [AG-15501, AG-13499] Funding Source: Medline
Ask authors/readers for more resources
Amyloid beta (A beta) is a small self-aggregating peptide produced at low levels by normal brain metabolism. In Alzheimer's disease (AD), self-aggregation of A beta becomes rampant, manifested most strikingly as the amyloid fibrils of senile plaques. Because fibrils can kill neurons in culture, it has been argued that fibrils initiate the neurodegenerative cascades of AD. An emerging and different view, however, is that fibrils are not the only toxic form of A beta, and perhaps not the neurotoxin that is most relevant to AD: small oligomers and protofibrils also have potent neurological activity. Immuno-neutralization of soluble A beta -derived toxins might be the key to optimizing AD vaccines that are now on the horizon.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available